Business Description
Zydus Lifesciences Ltd
ISIN : US1273961094
Share Class Description:
CDLYY: ADRCompare
Compare
Traded in other countries / regions
532321.India IPO Date
2014-12-29Description
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.72 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 72.26 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 9.58 | |||||
| Beneish M-Score | -2.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.9 | |||||
| 3-Year EBITDA Growth Rate | 20.1 | |||||
| 3-Year EPS without NRI Growth Rate | 16.5 | |||||
| 3-Year FCF Growth Rate | -1.3 | |||||
| 3-Year Book Growth Rate | 15.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.23 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.27 | |||||
| Quick Ratio | 1.58 | |||||
| Cash Ratio | 0.56 | |||||
| Days Inventory | 198.6 | |||||
| Days Sales Outstanding | 80.48 | |||||
| Days Payable | 111.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.6 | |||||
| Shareholder Yield % | 0.51 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.29 | |||||
| Operating Margin % | 25.8 | |||||
| Net Margin % | 20.62 | |||||
| ROE % | 21.38 | |||||
| ROA % | 14.91 | |||||
| ROIC % | 16.88 | |||||
| ROC (Joel Greenblatt) % | 50.48 | |||||
| ROCE % | 23.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.81 | |||||
| PE Ratio without NRI | 23.46 | |||||
| Shiller PE Ratio | 33.98 | |||||
| Price-to-Owner-Earnings | 30.03 | |||||
| PEG Ratio | 1.94 | |||||
| PS Ratio | 4.7 | |||||
| PB Ratio | 4.49 | |||||
| Price-to-Tangible-Book | 7.19 | |||||
| Price-to-Free-Cash-Flow | 42.41 | |||||
| Price-to-Operating-Cash-Flow | 30.5 | |||||
| EV-to-EBIT | 16.63 | |||||
| EV-to-EBITDA | 14.48 | |||||
| EV-to-Revenue | 4.56 | |||||
| EV-to-FCF | 40.97 | |||||
| Price-to-DCF (Earnings Based) | 1.75 | |||||
| Price-to-DCF (FCF Based) | 1.63 | |||||
| Price-to-Median-PS-Value | 1.33 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.34 | |||||
| Price-to-Graham-Number | 2.74 | |||||
| Price-to-Net-Current-Asset-Value | 38.6 | |||||
| Earnings Yield (Greenblatt) % | 6.01 | |||||
| FCF Yield % | 2.37 | |||||
| Forward Rate of Return (Yacktman) % | 13.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with GREY:CDLYY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zydus Lifesciences Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0.09 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0 - 0 | ||
| Shares Outstanding (Mil) | 2,047.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zydus Lifesciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zydus Lifesciences Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zydus Lifesciences Ltd Frequently Asked Questions
What is Zydus Lifesciences Ltd(CDLYY)'s stock price today?
The current price of CDLYY is $0.00. The 52 week high of CDLYY is $0.00 and 52 week low is $0.00.
When is next earnings date of Zydus Lifesciences Ltd(CDLYY)?
The next earnings date of Zydus Lifesciences Ltd(CDLYY) is .
Does Zydus Lifesciences Ltd(CDLYY) pay dividends? If so, how much?
Zydus Lifesciences Ltd(CDLYY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers